Publications

Hooda N, Suh M, Bylsma LC, Kelsh M. A systematic literature review of the association between dose reduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and survival in patients with HR-positive breast cancer (BC). Poster 1882eP, European Society for Medical Oncology (ESMO) Congress 2026, Madrid, Spain, October 23-27, 2026.

Bylsma L, Kelsh M, Jiang X, Mitchell M, Movva N, Sacks NC. To be or not to be a rare disease: An evaluation of prevalence estimates for cancers near the orphan status threshold. Poster O-008, National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, Washington, DC, October 25-27, 2026.

Bylsma L, Suh M, Movva N, Pastula S, Gauthier J, Itlzer R, Harrington A. 2026. Protocol for systematic literature review of efficacy/effectiveness, safety, and long-term impact of supportive care treatment in adults with primary mitochondrial diseases. PROSPERO 2026:CRD42026143005. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261434005.

Perreault L, Rasouli N, Sanogo F, Movva N, Bylsma L, Suh M, Reichert H, Donsmark M, Girguis M, Frankenfeld C. A meta-analysis of persistence and adherence to glucagon-like peptide 1-based treatments among patients with type 2 diabetes in the United States. Abstract/Poster 1691-P, American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, June 7, 2026.

Beggs AH, Haselkorn T, Solomon F, Rumantir R, Bylsma LC, Vue S, Mitchell M, Kelsh M, Sacks NC, Graham RJ. Epidemiology of x-linked myotubular myopathy (XLMTM) in the United States using a machine learning model. Abstract/Poster 106S, Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, Orlando, FL, March 2026.

Broome C, Hausrath D, Jaworski J, Fernandez S, Edwards T,…, Bylsma L, Kelsh M,.., Mitchell M. Survival outcomes of patients with secondary hemophagocytic lymphohistiocytosis at two academic medical centers in the United States. Poster 905, Blood 146(Sup 1):6243; doi: 10.1182/blood-2025-6243. 67^th American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, FL, November 2025.

Movva N, Bylsma L, Suh M, Kelsh M, Van Valkenburgh H, Zaha R. 2025. Systematic literature review of bioavailability of characteristics, clinical presentations, and outcomes among women with pregnancies affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT) and/or have anti-HPA-1a antibodies with no history of FNAIT. PROSPERO 2025:CRD420251153257. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251153257.

Bylsma LC, Gage SM, Reichert H, Dahl SLM, Lawson JH. 2017. Arteriovenous fistulas for hemodialysis: A systematic review and meta-analysis of efficacy and safety outcomes. Eur J Vasc Endovasc Surg 54(4):513-522; doi: 10.1016/j.ejvs.2017.06.024. PMID: 28843984.

Pastula ST, Bylsma LC, Rege SV, Lewis RJ, Movva N. 2025. Scoping review of indices to measure a community’s health status. Popul Health Manag 28(1):37-49; doi: 10.1089/pop.2024.0138. PMID: 39558762.

Kelsh M, Bylsma LC, Jiang X, Movva N, Sacks NC. To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40^th Annual Meeting, Berlin, Germany, August 2024.

Vincent MJ, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. 2024. Assessment of associations between inhaled formaldehyde and lymphohematopoietic cancer through the integration of epidemiological and toxicological evidence with biological plausibility. Toxicol Sci 199(2):172–193; doi: 10.1093/toxsci/kfae039. PMID: 38547404.

Vincent M, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024. 

Mitchell M, Suh M, Hooda N, Bylsma LC, Cohen S. 2024. The effect of bovine dairy products and their components on the incidence and natural history of infection: A systematic literature review. Nutr J 23(1):26; doi: 10.1186/s12937-024-00923-7. PMID: 38413931.

Suh M, Mitchell M, Hooda N, Bylsma LC, Cohen SS. 2024. The effects of dairy consumption on vaccine immune response and immunoglobulins: A systematic literature review. Int J Nutr 8(1):1–25; doi: 10.14302/issn.2379-7835.ijn-24-4938.

Movva N, Reichert H, Hooda N, Bylsma LC, Mitchell M, Cohen SS. 2023. Dietary eating patterns, dairy consumption, and anxiety: A systematic literature review. PLoS One 18(12):e0295975. doi: 10.1371/journal.pone.0295975. PMID: 38153944.

Bylsma LC, Pundole X, Ju C-H, Hooda N, Movva N, Elkhouly E, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Target Oncol 18(6):821-835; doi: 10.1007/s11523-023-01008-x. PMID: 37930513.

Pastula S, Bylsma LC, Movva N, Rege S, Lewis RJ, Fryzek JP. 2023. Scoping review of indices to monitor community health. Open Science Framework.

Movva N, Pastula ST, Rege SV, Lewis RJ, Bylsma LC. 2023. Scoping review of employer-led research using employee health claims data. Popul Health Manag 26(5):341-352; doi: 10.1089/pop.2023.0140. PMID: 37682577.

Mitchell ME, Bylsma LC, Shara NM, Fernandez SJ, Catlett JP, Lai JS, Dong K, Fryzek JP, et al. Novel methods for the identification of a rare disease, hemophagocytic lymphohistiocytosis (HLH). Poster 166, International Society for Pharmacoepidemiology Annual Meeting, Halifax, Nova Scotia, August 2023.

Broome CM, Mitchell M, Bylsma L, Shara N, Fernandez S, Catlett J, Lai J, Dong K, et al. Novel methods for the identification of a rare disease, hemophagocytic lymphohistiocytosis (HLH). Abstract P1202. Poster presented to European Hematology Association-EHA2023, Frankfurt, June 2023.